Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

Breast carcinomas are often infiltrated by inflammatory cells, particularly macrophages and T lymphocytes, but the significance of these cells remains unclear. One possible role of these inflammatory cells is that they represent a cell-mediated immune response against the carcinoma. CD8(+) lymphocytes are a known crucial component of cell-mediated immunity. The purpose of this study was to explore the prognostic value of tumor-infiltrating CD8(+) cytotoxic lymphocytes in breast cancer. Tumor-infiltrating CD8(+) lymphocytes were assessed by immunohistochemical staining of tissue microarray cores from 1,334 unselected breast tumors from patients with long-term follow-up. The number of CD8(+) T cells was counted in tumor nests (intratumoral), in stroma adjacent to tumor cells, and in stroma distant to tumor cells, and their relationship with clinical outcome was determined. The total number of CD8(+) cells was positively correlated with tumor grade (r(s) = 0.20; P < .001) and inversely correlated with patient's age at diagnosis, estrogen receptor-alpha (ER-α), and progesterone receptor (PgR) expression (Mann-Whitney U test, P < .001). The total patient cohort was randomly divided into two separate training and validation sets before performing univariate survival analysis. Total number and distant stromal CD8(+) lymphocytes were associated with better patient survival (P = .041 and P < .001, respectively) in the training set. In multivariate analysis, total CD8(+) T-cell count was an independent prognostic factor in both training and validation sets. These results suggest that tumor-infiltrating CD8(+) T lymphocytes have antitumor activity as judged by their favorable effect on patients' survival and could potentially be exploited in the treatment of breast cancer.

[1]  J. Petros,et al.  Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status , 2000, Breast Cancer Research and Treatment.

[2]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[3]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[4]  V. Kosma,et al.  Lymphocyte infiltrates as a prognostic variable in female breast cancer. , 1992, European journal of cancer.

[5]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[6]  Jack D Bui,et al.  Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? , 2007, Current opinion in immunology.

[7]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[8]  T. Oshikiri,et al.  CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.

[9]  I. Fentiman,et al.  Different patterns of inflammation and prognosis in invasive carcinoma of the breast , 2006, Histopathology.

[10]  M. Manjili,et al.  Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce “danger signals” , 2006, Breast Cancer Research and Treatment.

[11]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[12]  Douglas Macmillan,et al.  Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. , 2006, European journal of cancer.

[13]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[14]  A. Goldhirsch,et al.  Vaccine immunotherapy in breast cancer treatment: promising, but still early , 2007, Expert review of anticancer therapy.

[15]  G. Heppner,et al.  Immunological enhancement of breast cancer , 1997, Parasitology.

[16]  T. Cooke,et al.  Quantifying tumour-infiltrating lymphocyte subsets: a practical immuno-histochemical method. , 2007, Journal of immunological methods.

[17]  R. Blamey,et al.  Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long‐term follow‐up , 1992, Histopathology.

[18]  E. Jaffee,et al.  Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. , 2004, Breast disease.

[19]  S. Lakhani,et al.  Molecular evolution of breast cancer , 2005, The Journal of pathology.

[20]  Zlatko Trajanoski,et al.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Carbone,et al.  Decreased antigen presentation by dendritic cells in patients with breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  J. Hadden.  The immunology and immunotherapy of breast cancer: an update. , 1999, International journal of immunopharmacology.

[23]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Papamichail,et al.  Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer , 1994, Cancer.

[25]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[26]  Masakatsu Imamura,et al.  Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: An immunoperoxidase study with anti‐human t‐ and b‐cell sera , 1982 .

[27]  D. Cox.  Regression Models and Life-Tables , 1972 .

[28]  Gavin P Dunn,et al.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. , 2006, Advances in immunology.

[29]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[30]  J. Robertson,et al.  Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation , 2006, The Journal of pathology.

[31]  B K Jakobsen,et al.  Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. , 2000, Immunology today.

[32]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[33]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[34]  R. Poisson,et al.  Biological markers and breast cancer. A multiparametric study. II: Depressed immune competence , 1982, Cancer.

[35]  C. Janeway,et al.  Antigen Recognition by B-cell and T-cell Receptors , 2001 .

[36]  I. Ellis,et al.  Expression of BRCA1 protein in breast cancer and its prognostic significance. , 2008, Human pathology.

[37]  C. Gallo,et al.  Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer. , 1995, Oncology.

[38]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[39]  L. Happerfield,et al.  Angiogenesis and inflammation in invasive carcinoma of the breast. , 1997, Journal of clinical pathology.

[40]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[41]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  David L Rimm,et al.  Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. , 2006, Cancer research.

[43]  A. Gemma,et al.  Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer , 2008, Cancer.

[44]  D. Rimm,et al.  Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.

[45]  H Nagura,et al.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.

[46]  M. Sheaff,et al.  The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. , 2003, Surgery.

[47]  A. Marrogi,et al.  Study of tumor infiltrating lymphocytes and transforming growth factor‐β as prognostic factors in breast carcinoma , 1997, International journal of cancer.

[48]  I. Ellis,et al.  An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer , 2011, Breast Cancer Research and Treatment.

[49]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[51]  T. Whiteside.  The tumor microenvironment and its role in promoting tumor growth , 2008, Oncogene.

[52]  Teruhiko Yoshida,et al.  Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. , 2006, International journal of oncology.

[53]  S. Pinder,et al.  Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long‐term follow‐up , 1994, Histopathology.